Ovarian cancer with high-level focal <i>ERBB2</i> amplification responds to trastuzumab and pertuzumab.

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.

Thouvenin, Laure; Charrier, Mélinda; Clement, Sophie; Christinat, Yann; Tille, Jean-Christophe; Frigeri, Mauro; Homicsko, Krisztian; Michielin, Olivier; Bodmer, Alexandre; Chappuis, Pierre O; McKee, Thomas A; Tsantoulis, Petros.

Afiliación

Thouvenin L; Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
Charrier M; Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
Clement S; Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
Christinat Y; Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
Tille JC; Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
Frigeri M; Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
Homicsko K; Multidisciplinary Oncology Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Michielin O; Multidisciplinary Oncology Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Bodmer A; Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
Chappuis PO; Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
McKee TA; Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
Tsantoulis P; Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.